GSA Capital Partners LLP Sells 21,977 Shares of Natera, Inc. (NASDAQ:NTRA)

GSA Capital Partners LLP lowered its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 66.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 10,958 shares of the medical research company's stock after selling 21,977 shares during the period. GSA Capital Partners LLP's holdings in Natera were worth $1,391,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. SG Americas Securities LLC raised its stake in Natera by 1,073.1% during the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company's stock worth $7,118,000 after buying an additional 60,127 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Natera by 15.1% in the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company's stock worth $6,810,000 after purchasing an additional 9,781 shares during the period. Natixis acquired a new stake in Natera in the first quarter worth $758,000. Chartwell Investment Partners LLC grew its holdings in Natera by 37.9% in the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company's stock worth $5,243,000 after purchasing an additional 11,362 shares during the period. Finally, Baader Bank Aktiengesellschaft acquired a new stake in Natera in the second quarter worth $478,000. Institutional investors own 99.90% of the company's stock.

Natera Stock Performance

Shares of NASDAQ NTRA traded down $4.93 during midday trading on Thursday, hitting $156.04. The company's stock had a trading volume of 882,714 shares, compared to its average volume of 1,326,342. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. Natera, Inc. has a one year low of $52.01 and a one year high of $167.79. The firm has a market capitalization of $19.30 billion, a price-to-earnings ratio of -89.14 and a beta of 1.53. The stock has a fifty day moving average price of $126.04 and a 200 day moving average price of $114.84.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.88%. The business had revenue of $439.80 million during the quarter, compared to analysts' expectations of $361.43 million. During the same quarter in the previous year, the company earned ($0.95) EPS. The business's quarterly revenue was up 63.9% compared to the same quarter last year. On average, research analysts forecast that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Insider Activity

In other news, insider Solomon Moshkevich sold 256 shares of the company's stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total value of $30,737.92. Following the completion of the sale, the insider now owns 111,891 shares of the company's stock, valued at approximately $13,434,752.37. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Steven Leonard Chapman sold 5,024 shares of the company's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the sale, the chief executive officer now directly owns 195,686 shares in the company, valued at $25,141,737.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Solomon Moshkevich sold 256 shares of the company's stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total transaction of $30,737.92. Following the sale, the insider now owns 111,891 shares of the company's stock, valued at $13,434,752.37. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 29,881 shares of company stock valued at $3,733,983. Corporate insiders own 7.60% of the company's stock.

Analyst Upgrades and Downgrades

NTRA has been the subject of a number of research reports. Robert W. Baird raised their price target on shares of Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a report on Wednesday. Piper Sandler restated an "overweight" rating and issued a $150.00 price target on shares of Natera in a report on Friday, September 13th. StockNews.com cut shares of Natera from a "hold" rating to a "sell" rating in a report on Thursday. The Goldman Sachs Group lifted their price objective on shares of Natera from $125.00 to $140.00 and gave the company a "buy" rating in a report on Wednesday, October 16th. Finally, BTIG Research lifted their price objective on shares of Natera from $125.00 to $135.00 and gave the company a "buy" rating in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $137.65.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.